Drug
Spebrutinib clinical trials
Also written CC-292 and AVL-292.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2012 (3)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 1
Celgene (5) · The Lymphoma Academic Research Organisation (1) · Celgene Corporation (1)
Often tested with
Tested in the same studies.
Lenalidomide (2) · Rituximab (1) · Avadomide (1) · CC-223 (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
- One of Tyrosine Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses spebrutinib is read from its arms, and is right about nine times in ten.
Testing it · 7
- Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular LymphomaTerminatedPhase 1CelgeneNCT02031419Written as CC-292
- Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic LymphomaCompletedPhase 1CelgeneNCT01732861Written as CC-292
- Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaCompletedPhase 1CelgeneNCT01351935Written as AVL-292
- Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292CompletedPhase 1CelgeneNCT01692184Written as 50 mg AVL-292
- A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell LymphomaCompletedPhase 1The Lymphoma Academic Research OrganisationNCT01766583Written as CC-292 + lenalidomide
- Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid ArthritisCompletedPhase 2CelgeneNCT01975610Written as CC-292
- Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedPhase 1Celgene CorporationNCT01744626Written as CC-292
Given in every arm · 1 — spebrutinib is usual care beside what is tested
Codes
What other systems call spebrutinib · ClinicalTrials.gg INT006349
- MeSH (NLM) C583568spebrutinibOne source NLM
- UNII (FDA) DRU6NG543JSPEBRUTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27088846spebrutinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C97037SpebrutinibOne source FDA
- DrugBank DB11764One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C583568 | spebrutinib | One source NLM |
| UNII (FDA) | DRU6NG543J | SPEBRUTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27088846 | spebrutinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C97037 | Spebrutinib | One source FDA |
| DrugBank | DB11764 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.